{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T04:04:28Z","timestamp":1750565068915,"version":"3.41.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>The aim of this study was to investigate the role of <jats:sup>18<\/jats:sup>F-DCFPyL PET\/CT in the evaluation of prostate cancer (PC) patients after definitive treatment and with low-level prostate-specific antigen (PSA) level of \u22640.2 ng\/mL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>This retrospective study was conducted in PC patients who received definitive treatments with PSA level of \u22640.2 ng\/mL and underwent <jats:sup>18<\/jats:sup>F-DCFPyL PET\/CT within a 1-week interval of PSA examination, and without interval treatment change or history of other cancer. Patient and tumor characteristics at initial diagnosis, treatment regimens, and findings on <jats:sup>18<\/jats:sup>F-DCFPyL PET\/CT were collected. Patients with minimal 6-month (median, 11 months; range, 6\u201321 months) follow-up or definitive biopsy results of the suspected PET\/CT findings were included. Imagine findings were reached with consensus among experienced board-certified nuclear medicine physicians. Comprehensive follow-up and\/or biopsy results were used as definitive determination of presence or absence of disease. Comparisons between groups of positive and negative <jats:sup>18<\/jats:sup>F-DCFPyL PET\/CT were done by using descriptive statistics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 96 <jats:sup>18<\/jats:sup>F-DCFPyL PET\/CTs from 93 patients met the inclusion criteria. The median Gleason score (GS) of positive group is 8 (range, 6\u201310), whereas negative group is 7 (range, 6\u201310). The median age of positive group is 71 (range, 50\u201390), whereas negative group is 69 (range, 45\u201388). There were 49 positive (51%) and 47 negative <jats:sup>18<\/jats:sup>F-DCFPyL PET\/CTs (49%). Detection rates at PSA level of \u22640.1 and 0.2 ng\/mL were 58.7% (27\/46) and 44% (22\/50), respectively. The scan-based sensitivity, specificity, positive predictive value, and negative predictive value are 100%, 95%, 96%, and 100% in group with PSA level of \u22640.1 ng\/mL, and 100%, 97%, 95%, and 100% in group with PSA level of 0.2 ng\/mL, respectively. Sites of involvement on positive <jats:sup>18<\/jats:sup>F-DCFPyL PET\/CTs were prostate bed, pelvic lymph nodes, bone, chest and supraclavicular lymph nodes, lung, and adrenal glands. The SUV<jats:sub>max<\/jats:sub> value on positive lesions ranged from 1.9 to 141.4; the smallest positive lymph node was 0.4 cm. High GS of 8\u201310, known metastatic status (M1), presence of extraprostatic extension, presence of seminal vesicle invasion, and very high-risk PC are significantly associated with positive <jats:sup>18<\/jats:sup>F-DCFPyL PET\/CT results (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05). Of all analyzed treatment regimes, upfront surgery (radical prostatectomy with or without pelvic lymph node dissection) had strong correlation with negative PET\/CT results (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). If patients received ADT only, or ADT plus chemotherapy, the PET\/CT results were most likely positive (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.026). For other treatment regimes, there were no statistical differences between the groups (<jats:italic toggle=\"yes\">P<\/jats:italic> &gt; 0.05).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In the presence of low PSA level in PC patients after definitive treatment, <jats:sup>18<\/jats:sup>F-DCFPyL PET\/CT is most beneficial in detection of disease in patients with GS of 8 or higher at the time of diagnosis, and the ones who have history of ADT only, or ADT plus chemotherapy. There is excellent negative prediction value of <jats:sup>18<\/jats:sup>F-DCFPyL PET\/CT. However, there is no cutoff PSA level for <jats:sup>18<\/jats:sup>F-DCFPyL PET\/CT indication and no correlation between PSA level and SUV<jats:sub>max<\/jats:sub> of positive lesions on <jats:sup>18<\/jats:sup>F-DCFPyL PET\/CT.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004893","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T19:03:12Z","timestamp":1696618992000},"page":"1021-1027","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Diagnostic Performance of PSMA-Based 18F-DCFPyL PET\/CT in Prostate Cancer Patients After Definitive Treatment With PSA Level \u22640.2 ng\/mL"],"prefix":"10.1097","volume":"48","author":[{"given":"Yang","family":"Lu","sequence":"first","affiliation":[{"name":"Division of Diagnostic Imaging, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zenus J.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guofan","family":"Xu","sequence":"additional","affiliation":[{"name":"Division of Diagnostic Imaging, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhichao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tinsu","family":"Pan","sequence":"additional","affiliation":[{"name":"Division of Diagnostic Imaging, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Biostatistics"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/cncr.22372","article-title":"Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level","volume":"109","year":"2007","journal-title":"Cancer"},{"issue":"Suppl 1","key":"bib4-20250621","first-page":"5","article-title":"Molecular and cellular prostate biology: origin of prostate-specific antigen expression and implications for benign prostatic hyperplasia","volume":"93","year":"2004","journal-title":"BJU Int"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","year":"1999","journal-title":"JAMA"},{"key":"bib6-20250621","first-page":"716","article-title":"Current controversies in the management of biochemical failure in prostate cancer","volume":"10","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","year":"2017","journal-title":"Eur Urol"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/01.ju.0000134888.22332.bb","article-title":"Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results","volume":"172","year":"2004","journal-title":"J Urol"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.eururo.2007.01.015","article-title":"Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy","volume":"51","year":"2007","journal-title":"Eur Urol"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference","volume":"65","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.juro.2006.10.097","article-title":"Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes","volume":"177","year":"2007","journal-title":"J Urol"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","year":"2017","journal-title":"Eur Urol"},{"key":"bib13-20250621","first-page":"254ra125","article-title":"Tumor clone dynamics in lethal prostate cancer","volume":"6","year":"2014","journal-title":"Sci Transl Med"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00259-017-3723-3","article-title":"Therapy assessment in prostate cancer using choline and PSMA PET\/CT","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.eururo.2013.10.055","article-title":"Visceral disease in castration-resistant prostate cancer","volume":"65","year":"2014","journal-title":"Eur Urol"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","year":"2015","journal-title":"Cell"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"12448","DOI":"10.18632\/oncotarget.2558","article-title":"Early outcome prediction on 18F-fluorocholine PET\/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone","volume":"5","year":"2014","journal-title":"Oncotarget"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1097\/RLU.0000000000000849","article-title":"18F-Fluciclovine PET\/CT for the detection of prostate cancer relapse: a comparison to 11C-choline PET\/CT","volume":"40","year":"2015","journal-title":"Clin Nucl Med"},{"key":"bib19-20250621","first-page":"355","article-title":"Management of biochemically recurrent prostate cancer: ensuring the right treatment of the right patient at the right time","volume":"38","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.eururo.2013.05.025","article-title":"Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature","volume":"64","year":"2013","journal-title":"Eur Urol"},{"key":"bib21-20250621","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","year":"1997","journal-title":"Clin Cancer Res"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1148\/rg.2018170108","article-title":"Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls","volume":"38","year":"2018","journal-title":"Radiographics"},{"key":"bib23-20250621","first-page":"3192","article-title":"Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature","volume":"59","year":"1999","journal-title":"Cancer Res"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2559.2007.02635.x","article-title":"Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique","volume":"50","year":"2007","journal-title":"Histopathology"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with (18)F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","year":"2021","journal-title":"J Urol"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/bju.15152","article-title":"Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging 68 Ga-PSMA-11 positron emission tomography scans for men with prostate cancer: benign or malignant?","volume":"126","year":"2020","journal-title":"BJU Int"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic performance of 18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study","volume":"27","year":"2021","journal-title":"Clin Cancer Res"},{"key":"bib28-20250621","first-page":"6","article-title":"More advantages in detecting bone and soft tissue metastases from prostate cancer using (18)F-PSMA PET\/CT","volume":"22","year":"2019","journal-title":"Hell J Nucl Med"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1097\/RLU.0000000000002690","article-title":"18F-DCFPyL PET\/CT in a single large metastasis with prostate-specific antigen level of 856 ng\/mL","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2967\/jnumed.118.222513","article-title":"Lesion detection and interobserver agreement with advanced image reconstruction for (18)F-DCFPyL PET\/CT in patients with biochemically recurrent prostate cancer","volume":"61","year":"2020","journal-title":"J Nucl Med"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2967\/jnumed.119.226514","article-title":"Prospective evaluation of PSMA-targeted (18)F-DCFPyL PET\/CT in men with biochemical failure after radical prostatectomy for prostate cancer","volume":"61","year":"2020","journal-title":"J Nucl Med"},{"key":"bib32-20250621","doi-asserted-by":"crossref","first-page":"546","DOI":"10.2967\/jnumed.119.231654","article-title":"Prospective evaluation of (18)F-DCFPyL PET\/CT in biochemically recurrent prostate cancer in an academic center: a focus on disease localization and changes in management","volume":"61","year":"2020","journal-title":"J Nucl Med"},{"key":"bib33-20250621","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1007\/s00259-021-05354-8","article-title":"Patterns of disease detection using [(18)F]DCFPyL PET\/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: a prospective trial","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib34-20250621","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1007\/s00259-020-05143-9","article-title":"[18F]DCFPyL PET\/CT in detection and localization of recurrent prostate cancer following prostatectomy including low PSA < 0.5 ng\/mL","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib35-20250621","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2967\/jnumed.121.263262","article-title":"Appropriate use criteria for prostate-specific membrane antigen PET imaging","volume":"63","year":"2022","journal-title":"J Nucl Med"},{"key":"bib36-20250621","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/MNM.0000000000001228","article-title":"Diagnostic performance of F-18 fluciclovine PET\/CT in post-radical prostatectomy prostate cancer patients with rising prostate-specific antigen level \u22640.5 ng\/mL","volume":"41","year":"2020","journal-title":"Nucl Med Commun"},{"key":"bib37-20250621","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/RLU.0000000000003122","article-title":"Is there any role for 18F-fluciclovine PET\/CT in the presence of undetectable PSA in prostate cancer patients after definitive treatment?","volume":"45","year":"2020","journal-title":"Clin Nucl Med"},{"key":"bib38-20250621","first-page":"87","article-title":"Diagnostic performance of 18F-fluciclovine PET\/CT in prostate cancer patients with rising PSA level \u2264 0.5 ng\/ml after multiple treatment failures","volume":"11","year":"2021","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"bib39-20250621","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"(18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial","volume":"20","year":"2019","journal-title":"Lancet Oncol"},{"key":"bib40-20250621","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1097\/RLU.0000000000002703","article-title":"A prospective head-to-head comparison of 18F-fluciclovine with 68Ga-PSMA-11 in biochemical recurrence of prostate cancer in PET\/CT","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib41-20250621","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0022-5347(01)66713-2","article-title":"The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies","volume":"154","year":"1995","journal-title":"J Urol"},{"key":"bib42-20250621","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000020289","article-title":"Low PSA metastatic androgen-independent prostate cancer","volume":"38","year":"2000","journal-title":"Eur Urol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:07:22Z","timestamp":1750532842000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004893","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2023,10,5]]}}}